Download PDF
Zentralbl Chir 2022; 147(03): 249-255
DOI: 10.1055/a-1826-3423
Übersicht

Theranostics bei gut bis mäßig differenzierten GEP-NEN

Theranostics for Well and Moderately Differentiated GEP-NEN
Philipp Hartrampf 
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Würzburg, Würzburg, Deutschland (Ringgold ID: RIN27207)
,
Rudolf Werner
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Würzburg, Würzburg, Deutschland (Ringgold ID: RIN27207)
,
Andreas Buck 
1   Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Würzburg, Würzburg, Deutschland (Ringgold ID: RIN27207)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Neuroendokrine Neoplasien (NEN) sind seltene, heterogene und typischerweise langsam wachsende Tumoren. Die häufigsten Lokalisationen finden sich im gastro-entero-pankreatischen System (GEP-NEN). NENs werden nach proliferativer Aktivität (Ki-67-Index) eingeteilt (G1–3). Gut differenzierte Tumoren exprimieren dabei typischerweise Somatostatinrezeptoren (SSTR), die als Zielstruktur in der nuklearmedizinischen Theranostik dienen. Bei diesem Prinzip kann nach einer diagnostischen molekularen Bildgebung, meist mittels Positronenemissionstomografie/Computertomografie (PET/CT), eine individuell zugeschnittene Peptidradiorezeptortherapie (PRRT) mit einem β-Strahler-markierten Radiopharmakon erfolgen. In Metaanalysen zeigte die Diagnostik mittels SSTR-gerichteter PET/CT eine Sensitivität von 93% und eine Spezifität von 96%. Die SSTR-gerichtete Diagnostik kann auch zur radioaktiven Markierung von Tumoren verwendet werden, um eine zielgerichtete Chirurgie zu ermöglichen. Die Indikation zur Einleitung einer PRRT soll stets in einer interdisziplinären Tumorkonferenz getroffen werden. Ein Tumorprogress unter der vorangegangenen Therapie sollte dokumentiert sein. Die Therapie wird intravenös und insgesamt 4-mal in 8-wöchigem Abstand in spezialisierten nuklearmedizinischen Zentren verabreicht. Die Wirksamkeit der PRRT wurde in der NETTER-1-Studie prospektiv untersucht und konnte eine signifikante Verbesserung des progressionsfreien Überlebens (primärer Endpunkt) zeigen. Ausgehend von diesen Studienergebnissen steht mit Lutathera (177Lu-DOTATATE) inzwischen ein in Deutschland zugelassenes Radiopharmazeutikum zu Behandlung von nicht resektablen oder metastasierten bzw. progredienten, gut differenzierten (G1 und G2), SSTR-positiven GEP-NEN zur Verfügung.

Abstract

Neuroendocrine neoplasms (NEN) are rare, heterogeneous, and typically slowly growing tumours. The most common location is the gastro-entero-pancreatic system (GEP-NEN). NENs are classified according to their proliferative activity (Ki-67 index, G1–3). In this context, well-differentiated tumours typically express somatostatin receptors (SSTR), thus serving as targets for nuclear medicine theranostics. In this approach, diagnostic molecular imaging, usually by positron emission tomography/computed tomography (PET/CT), can be followed by individually tailored peptide radioreceptor therapy (PRRT) with a β-emitter labeled radiopharmaceutical. In meta-analyses, diagnostics using SSTR-directed PET/CT showed a sensitivity of 93% and a specificity of 96%. SSTR-directed diagnostics can also be used to trace tumours in-vivo, enabling radioguided surgery. The decision to initiate PRRT should always be made in an interdisciplinary tumour conference and tumour progression during previous therapy should be documented. This treatment is administered intravenously for 4 times at 8-week intervals in specialised nuclear medicine centres. PRRT efficacy was prospectively evaluated in the NETTER-1 study and demonstrated a significant improvement in progression-free survival (primary endpoint). Based on these results, Lutathera (177Lu-DOTATATE) is now available as a radiopharmaceutical approved in Germany for the treatment of non-resectable or metastatic or progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NEN.

Schlüsselwörter

neuroendokrine Tumoren - Peptid Radiorezeptor Therapie - Somatostatinrezeptoren - PET/CT - Nuklearmedizin

Keywords

neuroendocrine tumors - peptide radioreceptor therapy - somatostatin receptors - PET/CT - nuclear medicine


Publication History

Received: 07 February 2022

Accepted after revision: 11 April 2022

Article published online:
15 June 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Dasari A, Shen C, Halperin D. et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3: 1335-1342
    CrossrefPubMedSearch in Google Scholar
  • 2 Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin 2018; 68: 471-487
    CrossrefPubMedSearch in Google Scholar
  • 3 Sackstein PE, O’Neil DS, Neugut AI. et al. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol 2018; 45: 249-258
    CrossrefPubMedSearch in Google Scholar
  • 4 Perren A, Couvelard A, Scoazec JY. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology 2017; 105: 196-200
    CrossrefPubMedSearch in Google Scholar
  • 5 Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198
    CrossrefPubMedSearch in Google Scholar
  • 6 Papotti M, Bongiovanni M, Volante M. et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440: 461-475
    CrossrefPubMedSearch in Google Scholar
  • 7 Rinke A, Müller HH, Schade-Brittinger C. et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27: 4656-4663
    CrossrefPubMedSearch in Google Scholar
  • 8 Caplin ME, Pavel M, Ćwikła JB. et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371: 224-233
    CrossrefPubMedSearch in Google Scholar
  • 9 Werner RA, Bluemel C, Allen-Auerbach MS. et al. 68Gallium- and 90Yttrium-/ 177Lutetium: “theranostic twins” for diagnosis and treatment of NETs. Ann Nucl Med 2015; 29: 1-7
    CrossrefPubMedSearch in Google Scholar
  • 10 Ilhan H, Lindner S, Todica A. et al. Biodistribution and first clinical results of (18)F-SiFAlin-TATE PET: a novel (18)F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2020; 47: 870-880
    Search in Google Scholar
  • 11 Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002; 32: 84-91
    CrossrefPubMedSearch in Google Scholar
  • 12 Bombardieri E, Ambrosini V, Aktolun C. et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010; 37: 1441-1448
    CrossrefPubMedSearch in Google Scholar
  • 13 Chiti A, Fanti S, Savelli G. et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998; 25: 1396-1403
    CrossrefPubMedSearch in Google Scholar
  • 14 Wong KK, Cahill JM, Frey KA. et al. Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol 2010; 17: 291-297
    CrossrefPubMedSearch in Google Scholar
  • 15 Lee I, Paeng JC, Lee SJ. et al. Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and (111)In-Pentetreotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report. Nucl Med Mol Imaging 2015; 49: 284-290
    CrossrefPubMedSearch in Google Scholar
  • 16 Van Binnebeek S, Vanbilloen B, Baete K. et al. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol 2016; 26: 900-909
    CrossrefPubMedSearch in Google Scholar
  • 17 Hope TA, Bergsland EK, Bozkurt MF. et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59: 66-74
    CrossrefPubMedSearch in Google Scholar
  • 18 Rinke A, Wiedenmann B, Auernhammer C. Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (federführend). et al. S2k-Leitlinie Neuroendokrine Tumore. Z Gastroenterol 2018; 56: 583-681
    Search in Google Scholar
  • 19 Boy C, Poeppel T, Kotzerke J. et al. Somatostatinrezeptor-PET/CT. Nuklearmedizin 2018; 57: 4-17
    Thieme ConnectPubMedSearch in Google Scholar
  • 20 Poeppel TD, Binse I, Petersenn S. et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011; 52: 1864-1870
    CrossrefPubMedSearch in Google Scholar
  • 21 Kabasakal L, Demirci E, Ocak M. et al. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39: 1271-1277
    CrossrefPubMedSearch in Google Scholar
  • 22 Graham MM, Gu X, Ginader T. et al. (68)Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis. J Nucl Med 2017; 58: 1452-1458
    CrossrefPubMedSearch in Google Scholar
  • 23 Deppen SA, Blume J, Bobbey AJ. et al. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Nucl Med 2016; 57: 872-878
    CrossrefPubMedSearch in Google Scholar
  • 24 Deppen SA, Liu E, Blume JD. et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med 2016; 57: 708-714
    CrossrefPubMedSearch in Google Scholar
  • 25 Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2013; 40: 1770-1780
    CrossrefPubMedSearch in Google Scholar
  • 26 Treglia G, Castaldi P, Rindi G. et al. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012; 42: 80-87
    CrossrefPubMedSearch in Google Scholar
  • 27 Werner RA, Solnes LB, Javadi MS. et al. SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. J Nucl Med 2018; 59: 1085-1091
    CrossrefPubMedSearch in Google Scholar
  • 28 Tessler FN, Middleton WD, Grant EG. et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol 2017; 14: 587-595
    Search in Google Scholar
  • 29 [Anonym]. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, AWMF Registernummer: 032–045OL. 2021 Accessed February 03, 2022 at: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/
    PubMedSearch in Google Scholar
  • 30 [Anonym]. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.3, AWMF Registernummer: 032/024OL. 2020 Accessed February 03, 2022 at: http://www.leitlinienprogramm-onkologie.de/leitlinien/melanom/
    PubMedSearch in Google Scholar
  • 31 Schmidt M, Bares R, Brenner W, Buck A, Grünwald F, Kopp J, Krause BJ, Schober O, Sciuk J, Sudbrock F, Wengenmair H. DGN-Handlungsempfehlung (S1-Leitlinie), Verfahrensanweisung für die technische Durchführung der nuklearmedizinischen Wächter-Lymphknoten-Diagnostik, AWMF-Registernummer 031–033. Accessed February 03, 2022 at: https://www.nuklearmedizin.de/leistungen/leitlinien/docs/031–033l_S1_Waechter_Lymphknoten_Diagnostik_2014–10.pdf
    PubMed
  • 32 Cockburn KC, Toumi Z, Mackie A. et al. Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumours: a Systematic Literature Review. J Gastrointest Surg 2021; 25: 3244-3257
    CrossrefPubMedSearch in Google Scholar
  • 33 Krenning EP, Valkema R, Kooij PP. et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol 1999; 31: S219-S223
    PubMedSearch in Google Scholar
  • 34 Bodei L, Ambrosini V, Herrmann K. et al. Current Concepts in (68)Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies. J Nucl Med 2017; 58: 1718-1726
    CrossrefPubMedSearch in Google Scholar
  • 35 Werner RA, Bengel FM, Derlin T. Theranostics and hybrid imaging for somatostatin receptor-expressing tumors. Radiologe 2020; 60: 413-420
    CrossrefPubMedSearch in Google Scholar
  • 36 Bodei L, Mueller-Brand J, Baum RP. et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40: 800-816
    CrossrefPubMedSearch in Google Scholar
  • 37 Poeppel TD, Boy C, Bockisch A, Kotzerke J, Buchmann I, Ezziddin S, Scheidhauer K, Krause BJ, Schmidt D, Amthauer H, Rösch F, Nagarajah J, Führer D, Lahner H, Pöpperl G, Hörsch D, Walter MA, Baum RP. DGN-Handlungsempfehlung (S1-Leitlinie), Peptid-Rezeptor-Radionuklid-Therapie (PRRT) somatostatinrezeptorexprimierender Tumore, AWMF-Registernummer: 031–045. Accessed February 03, 2022 at: https://www.nuklearmedizin.de/leistungen/leitlinien/docs/031–045_131216.pdf
    PubMed
  • 38 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376: 125-135
    CrossrefPubMedSearch in Google Scholar
  • 39 Strosberg J, Wolin E, Chasen B. et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With (177)Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 2018; 36: 2578-2584
    CrossrefPubMedSearch in Google Scholar
  • 40 Strosberg JR, Caplin ME, Kunz PL. et al. 177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1. Lancet Oncol 2021; 22: 1752-1763
    CrossrefPubMedSearch in Google Scholar
  • 41 Mansi R, Plas P, Vauquelin G. et al. Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE. Pharmaceuticals (Basel) 2021; 14
    CrossrefPubMedSearch in Google Scholar
  • 42 Nicolas GP, Schreiter N, Kaul F. et al. Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. J Nucl Med 2018; 59: 915-921
    CrossrefPubMedSearch in Google Scholar
  • 43 Reidy DL, Pandit-Taskar N, Krebs S. et al. Theranostic trial of well differentiated neuroendocrine tumors (NETs) with somatostatin antagonists 68Ga-OPS202 and 177Lu-OPS201. Journal of Clinical Oncology 2017; 35: 4094-4094
    CrossrefPubMedSearch in Google Scholar
  • 44 Nicolas G, Baum R, Herrmann K. et al. Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours. Endocrine Abstracts 2017; 52: P36
    PubMedSearch in Google Scholar